Novartis showcases its attractive growth pipeline

Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint

Funding push to pharma R&D critical for unleashing next phase of growth

The industry is at an inflection point and it awaits mega investments, the right government policies, and the creation of a strong ecosystem to propel innovation

Illumina and Sequoia Capital China selects startups for Genomics

First-of-its-kind Incubator will support companies poised to deliver breakthrough applications in genomics and multiomics

J.B Chemicals & Pharmaceuticals PAT at Rs 98 cr. in Q2FY22

J. B. Chemicals & Pharmaceuticals Limited (JBCPL), announced its financial results for the second quarter ended 30th September, 2021

Strides Pharma Science incurs Rs 162.55 cr. loss in Q2FY22

Strides Pharma Science has reported consolidated financial results for the period ended September 30, 2021

Sun Pharma Q2FY22 PAT jumps to Rs 2088.73 Cr

Sun Pharma has reported consolidated financial results for the period ended September 30, 2021.

GlaxoSmithKline posts Q2FY22 consolidated PAT at Rs. 204.24 Cr

GlaxoSmithKline Pharmaceuticals Limited has reported consolidated financial results for the period ended September 30, 2021

Transforming Healthcare Through AI

Cipla consolidated net profit at Rs 711.36 cr. in Q2FY22

Cipla has reported consolidated financial results for the period ended September 30, 2021

Gland Pharma PAT declines to Rs 302 crore QoQ in Q2FY22

The company’s wide therapeutic portfolio helped to sustain growth despite changing market demand